Phase 3 RCT in 745 men with intermediate/high-risk localised prostate cancer having radiotherapy: aglatimagene plus valacyclovir lengthened disease-free survival vs placebo plus valacyclovir (median not reached vs 86.1 months; HR 0.70).
RCTn = 745
DeWeese et al. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial